;

:

–

Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue- selective amyloid disease. Cell.

;

:

–

Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science.

;

:

–

Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science.

;

:

–

Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, Shoji S, Okuyama M, Ideta H, Nakagawa K, Ishizaki T, Ando M, Saraiva MJ. A novel compound heterozygote (FAP ATTR Arg

His/ATTR Val

Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun.

;

:

–

Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ. Thyroxine binding to transthyretin Met

Comparative studies of different hetero- zygotic carriers and structural analysis. Endocrine.

;

:

–

Curtis AJ, Scrimshaw BJ, Topliss DJ, Stockigt JR, George PM, Barlow JW. Thyroxine binding by human transthyretin variants: mutations at posi- tion

, but not position

, increase thyroxine binding affinity. J Clin Endocrinol Metab.

;

:

–

Alves IL, Divino CM, Schussler GC, Altland K, Almeida MR, Palha JA, Coelho T, Costa PP, Saraiva MJ. Thyroxine binding in a TTR Met

kindred. J Clin Endocrinol Metab.

;

:

–

Lim A, Prokaeva T, Connor LH, Falk RH, Skinner M, Costello CE. Identification of a novel transthyretin Thr

Lys/Arg

His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid.

;

:

–

Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal.

;

:

–

Schussler GC. The thyroxine-binding proteins. Thyroid.

;

:

–

Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyre- tin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology.

;

:

–

Harrison HH, Gordon ED, Nichols WC, Benson MD. Biochemical and clinical characterization of prealbumi

HICAGO: an apparently benign variant of serum prealbumin (transthyretin) discovered with high-res- olution two-dimensional electrophoresis. Am J Med. Genet.

;

:

–

Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clear- ance of [Met

]transthyretin and [Met

]transthyretin. Eur J Biochem.

;

:

–

Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. transthyretin amyloid fibril formation via protein stabilization. Proc Acad Sci U S A.

;

:

–

Yamano M, Azuma A, Yazaki M, Ikeda S, Sawada T, Matsubara Early cardiac involvement in senile systemic amyloidosis: a case Amyloid.

;

:

–

Nakagawa M, Tojo K, Sekijima Y, Yamazaki KH, Ikeda S. Arterial boembolism in senile systemic amyloidosis: report of two cases.

;

:

–

Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, B. Sporadic and familial cerebral amyloid angiopathies. Brain

;

:

–

Li X, Buxbaum JN. Transthyretin and the brain re-visited: is nal synthesis of transthyretin protective in Alzheimer’s disease? Neurodegener.

;

:

Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle Transthyretin sequesters amyloid beta protein and prevents amyloid mation. Proc Natl Acad Sci U S A.

;

:

–

Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer’s mice the behavioral and biochemical effects of Abeta toxicity. Proc Natl Sci U S A.

;

:

–

Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve eration. J Neurochem.

;

:

–

Santos SD, Lambertsen KL, Clausen BH, Akinc A, Alvarez R, Finsen Saraiva MJ. CSF transthyretin neuroprotection in a mouse model of ischemia. J Neurochem.

;

:

–

Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach Mechanisms of transthyretin cardiomyocyte toxicity inhibition resveratrol analogs. Biochem Biophys Res Commun.

;

:

–

Zhao L, Buxbaum JN, Reixach N. Age-related oxidative tions of transthyretin modulate its amyloidogenicity.

;

:

–

Ferreira N, Santos SA, Domingues MR, Saraiva MJ, Almeida MR. curcumin counteracts extracellular transthyretin deposition: insights on mechanism of amyloid inhibition. Biochim Biophys Acta.

Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-

-gallate as potential therapeutic drug for TTR-related amyloidosis: “in vivo” dence from FAP mice models. PL

One.

;

:e

Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of diac transthyretin amyloidosis: an observational report. Clin Res

;

:

–

Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteros Barluenga J, Pérez JJ, Vázquez JT, Centeno NB, Saraiva MJ, Damas Planas A, Arsequell G, Valencia G. Iodine atoms: a new molecular for the design of potent transthyretin fibrillogenesis inhibitors. PL

;

:e

NHLBI Exome Sequencing Project (ESP) Exome Variant Server. evs.gs.washington.edu/EVS/. Accessed November

Significance